Clinical trial
Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)
NCT04684914 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)
- Lead sponsor
- Altimmune, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 26, 2020
- Completion date
- April 17, 2024
- Enrollment
- 87 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.